A randomised clinical trial of 10-day concomitant therapy and standard triple therapy for Helicobacter pylori eradication

Daegu-Gyeongbuk Gastrointestinal Study Group

Research output: Contribution to journalArticlepeer-review

27 Scopus citations

Abstract

Background: As a result of increased resistance to antibiotics, Helicobacter pylori eradication rates using standard triple therapy have been declining. Aim: To validate the efficacy and tolerability of a concomitant regimen as a first-line treatment for H. pylori infection. Methods: A total of 348 naïve H. pylori-infected patients from six hospitals in Korea were randomly assigned to concomitant therapy and standard triple therapy groups. The concomitant regimen consisted of 30. mg of lansoprazole, 1. g of amoxicillin, 500. mg of clarithromycin, and 500. mg of metronidazole, twice daily for 10 days. The standard triple regimen consisted of 30. mg of lansoprazole, 1. g of amoxicillin, and 500. mg of clarithromycin, twice daily for 10 days. Results: Concomitant and standard eradication rates were 78.7% (137/174) vs. 70.7% (123/174) by intention-to-treat (. p=. 0.084) and 88.7% (133/150) vs. 78.4% (120/153) by per-protocol (. p=. 0.016), respectively. The two groups were similar with regard to the incidence of adverse events. Conclusions: Although 10-day concomitant therapy was validated as a suboptimal treatment option for the treatment of H. pylori infection, this regimen is expected to be a promising starting point in the development of an optimal treatment regimen for H. pylori infection.

Original languageEnglish
Pages (from-to)980-984
Number of pages5
JournalDigestive and Liver Disease
Volume46
Issue number11
DOIs
StatePublished - 1 Nov 2014

Keywords

  • Concomitant therapy
  • Helicobacter
  • Standard therapy

Fingerprint

Dive into the research topics of 'A randomised clinical trial of 10-day concomitant therapy and standard triple therapy for Helicobacter pylori eradication'. Together they form a unique fingerprint.

Cite this